Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy.

Updates clinicians on long-term kidney preservation outcomes for a novel dual endothelin/angiotensin receptor antagonist in glomerular disease management.